Skip to Content

Join the 'Severe Pain' group to help and get support from people like you.

Severe Pain News

FDA Approves Targiniq ER Extended-Release Oxycodone with Abuse-Deterrent Properties

Posted 23 Jul 2014 by Drugs.com

July 23, 2014 – Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Targiniq ER is the second ER/LA opioid analgesic with FDA-approved labeling describing the product’s abuse-deterrent properties consistentwith the FDA’s 2013 draft guidance for industry, Abuse-Deterrent Opioids – Evaluation and Labeling. Targiniq ER has properties that are expected to deter, but not totally prevent, abuse of the drug by snorting and injection. When crushed and snorted, or crushed, dissolved and injected, the naloxone in Targiniq ER blocks the euphoric effects of oxycodone, making it less liked by abusers th ... Read more

Related support groups: Pain, Oxycodone, Chronic Pain, Severe Pain, Naloxone

Ask a Question